Spearman correlations between the PsAID scores and other measures of health status
| Comparative measure of health | PsAID-12 correlation R | PsAID-9 correlation R |
|---|---|---|
| Patient global assessment | 0.843 (p<0.0001) | 0.840 (p<0.0001) |
| Patient global (joints) | 0.836 (p<0.0001) | 0.845 (p<0.0001) |
| Patient global (neck, back, hip pain) | 0.709 (p<0.0001) | 0.711 (p<0.0001) |
| Patient global (psoriasis) | 0.554 (p<0.0001) | 0.550 (p<0.0001) |
| SF-36 aggregated physical score | −0.725 (p<0.0001) | −0.731 (p<0.0001) |
| SF-36 aggregated emotional score | −0.597 (p<0.0001) | −0.578 (p<0.0001) |
| HAQ | 0.723 (p<0.0001) | 0.721 (p<0.0001) |
| Pain numeric assessment | 0.834 (p<0.0001) | 0.842 (p<0.0001) |
| DLQI | 0.422 (p<0.0001) | 0.408 (p<0.0001) |
| EQ-5D | −0.758 (p<0.0001) | −0.752 (p<0.0001) |
| DAS28-ESR | 0.547 (p<0.0001) | 0.546 (p<0.0001) |
| Physician global assessment | 0.530 (p<0.0001) | 0.530 (p<0.0001) |
Patient global assessment was evaluated by four global questions.
DAS28, Disease Activity Score (28 joints); DLQI, Dermatology Life Quality Index; EQ-5D, EuroQol-5D; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; PsAID, Psoriatic Arthritis Impact of Disease; SF-36, short form (36) generic quality of life scale.